April 16, 2020 -- Scripps Research has pivoted its drug repurposing collection ReFRAME to find antiviral compounds effective against the novel coronavirus.
Researchers from Scripps' drug development division Calibr will work with scientists from around the world to look for compounds from individual drugs or drug combinations that could treat patients with COVID-19. It is part of an accelerator launched by the Bill & Melinda Gates Foundation to develop COVID‑19 therapeutics.
ReFrame's collection includes 14,000 compounds, including medications already repurposed for disease treatment. Calibr created the collection in 2018 to address tropical diseases and other unmet medical needs.